Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.

Adult Amides Antiviral Agents / pharmacokinetics Atazanavir Sulfate / pharmacokinetics Benzofurans / pharmacokinetics Carbamates Cyclopropanes Darunavir / pharmacokinetics Drug Interactions Female HIV Infections / drug therapy HIV Protease Inhibitors / pharmacokinetics HIV-1 / drug effects Healthy Volunteers Hepacivirus / drug effects Hepatitis C / drug therapy Humans Imidazoles / pharmacokinetics Intracellular Signaling Peptides and Proteins / antagonists & inhibitors Lopinavir / pharmacokinetics Male Middle Aged Quinoxalines / pharmacokinetics Ritonavir / pharmacokinetics Sulfonamides Viral Nonstructural Proteins / antagonists & inhibitors Young Adult

atazanavir darunavir elbasvir grazoprevir lopinavir ritonavir virology

Journal

Antimicrobial agents and chemotherapy

ISSN: 1098-6596

Titre abrégé: Antimicrob Agents Chemother

Pays: United States

ID NLM: 0315061

Informations de publication

Date de publication:
04 2019

Historique:

received: 10 10 2018

accepted: 11 01 2019

pubmed: 13 2 2019

medline: 13 3 2020

entrez: 13 2 2019

Statut: epublish

Résumé

The combination of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir is a potent, once-daily therapy indicated for the treatment of chronic HCV infection in individuals coinfected with human immunodeficiency virus (HIV). We explored the pharmacokinetic interactions of elbasvir and grazoprevir with ritonavir and ritonavir-boosted HIV protease inhibitors in three phase 1 trials. Drug-drug interaction trials with healthy participants were conducted to evaluate the effect of ritonavir on the pharmacokinetics of grazoprevir (

Identifiants

DOI: 10.1128/AAC.02142-18 PMID: 30745392 PMC: PMC6437487

pubmed: 30745392

pii: AAC.02142-18

doi: 10.1128/AAC.02142-18

pmc: PMC6437487

pii:

doi:

Substances chimiques

Amides 0

Antiviral Agents 0

Benzofurans 0

Carbamates 0

Cyclopropanes 0

HIV Protease Inhibitors 0

Imidazoles 0

Intracellular Signaling Peptides and Proteins 0

NS3 protein, hepatitis C virus 0

NS4A cofactor peptide, Hepatitis C virus 0

Quinoxalines 0

Sulfonamides 0

Viral Nonstructural Proteins 0

Lopinavir 2494G1JF75

Atazanavir Sulfate 4MT4VIE29P

grazoprevir 4O2AB118LA

elbasvir 632L571YDK

NS-5 protein, hepatitis C virus EC 2.7.7.48

Ritonavir O3J8G9O825

Darunavir YO603Y8113

Types de publication

Clinical Trial, Phase I Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Lancet. 2015 Oct 17;386(10003):1537-45

pubmed: 26456905

Medicine (Baltimore). 2017 Jun;96(26):e7348

pubmed: 28658155

Ann Intern Med. 2016 Nov 1;165(9):625-634

pubmed: 27537841

Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7

pubmed: 22615282

Ann Intern Med. 2015 Jul 7;163(1):1-13

pubmed: 25909356

Gastroenterology. 2017 Jan;152(1):164-175.e4

pubmed: 27720838

Xenobiotica. 2010 Mar;40(3):163-76

pubmed: 20102298

Clin Infect Dis. 2016 Apr 15;62(8):972-9

pubmed: 26740513

Lancet HIV. 2015 Aug;2(8):e319-27

pubmed: 26423374

Br J Clin Pharmacol. 2016 May;81(5):929-40

pubmed: 26710243

J Pharm Sci. 2011 Sep;100(9):3636-54

pubmed: 21698598

Clin Pharmacol Ther. 2007 Feb;81(2):194-204

pubmed: 17192770

Hepatology. 2017 Feb;65(2):439-450

pubmed: 27770561

Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):1015-1022

pubmed: 28753040

J Antimicrob Chemother. 2019 Mar 1;74(3):710-717

pubmed: 30541077

Clin Pharmacol Ther. 2011 Oct;90(4):575-81

pubmed: 21832990

Clin Infect Dis. 2012 Jul;55 Suppl 1:S33-42

pubmed: 22715212

Lancet. 2015 Mar 21;385(9973):1075-86

pubmed: 25467591

Gastroenterology. 2014 Aug;147(2):366-76.e6

pubmed: 24727022

Clin Infect Dis. 2001 Aug 15;33(4):562-9

pubmed: 11462196

J Hepatol. 2016 Dec;65(6):1112-1119

pubmed: 27542322

ChemMedChem. 2013 Dec;8(12):1930-40

pubmed: 24127258